JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 46(2012) N 1 p. 65-74;
D.S. Mikhaylenko1,2,3*, M.V. Grigor'eva5, I.G. Rusakov5, R.V. Kurynin6, A.M. Popov7, M.V. Peters4, V.B. Matveev4, E.S. Yakovleva4, D.A. Nosov4, L.N. Lyubchenko4, S.A. Tulyandin4, V.V. Strel'nikov2, 3, D.V. Zaletaev1,2,3

Localization of Point Mutations in the Coding Part of the VHL Gene in Clear Cell Renal Cancer

1Medical-Biological Faculty, Russian State Medical University, Moscow, 117997 Russia
2Research Centre for Medical Genetics, Russian Academy of Medical Sciences, Moscow, 115478 Russia
3Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, 119991 Russia
4Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, 115478 Russia
5Herzen Oncological Research Institute, Moscow, 125284 Russia
6Fronstein Clinic of Urology, Sechenov First Moscow State Medical University, Moscow, 119991 Russia
7Medical Radiological Research Center, Ministry of Health Care and Social Development, Obninsk, 249036 Russia

*dimserg@mail.ru
Received - 2011-03-29; Accepted - 2011-04-29

The VHL gene is often inactivated in sporadic clear cell renal cancer (CCRC) due to somatic mutations, and its germline mutations cause hereditary CCRC: von Hippel-Lindau syndrome. Localization of mutations in VHL, identification of new mutations, and their influence on CCRC progression and sensitivity to targeted therapy are topical problems in modern oncogenetics. In the current work, we identified and characterized mutations in 248 primary CCRCs using SSCP-analysis and sequencing. Somatic mutations were detected in 37.5% of samples, with 72% of mutations identified for the first time. New missense-mutations were analyzed by alignment programs and three-dimensional structure modeling. Mutation frequency was compared in differ- ent groups of patients with respect to stage, grade, and metastases. It was demonstrated that 39.1% of samples of stage I harbored somatic mutations; however, no association with progression or metastases was found. We also investigated localization of mutations in the VHL coding part and positions of missense-mutations and inframe deletions/insertions, focusing on VHL critical sequences. The VHL mutation analysis performed in this study expands the opportunities of laboratory diagnostics of familial and sporadic CCRC.

VHL gene, mutation, protein domain, renal cancer



JMB-FOOTER RAS-JOURNALS